More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.36B
EPS
-1.02
P/E ratio
--
Price to sales
5.85
Dividend yield
--
Beta
0.378521
Previous close
$45.73
Today's open
$45.81
Day's range
$44.99 - $46.19
52 week range
$33.01 - $73.30
CEO
Daniel Faga
Employees
104
Headquarters
San Diego, CA
Exchange
Nasdaq Global Select
Shares outstanding
29729847
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
AnaptysBio, Inc. (ANAB) Presents at UBS Global Biopharma Conference 2026 Transcript
AnaptysBio, Inc. ( ANAB ) UBS Global Biopharma Conference 2026 November 17, 2026 11:40 AM EST Company Participants Daniel Faga - President, CEO & Director Conference Call Participants Madeleine Lee - UBS Investment Bank, Research Division Presentation Madeleine Lee UBS Investment Bank, Research Division All right. So I think we'll get started with our last fireside of the day.
Seeking Alpha • a day ago

Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported financial results for the fiscal first quarter ended September 30, 2026, and provided a business update.
GlobeNewsWire • Nov 12, 2026

AnaptysBio, Inc. (ANAB) Misses Q3 Earnings and Revenue Estimates
AnaptysBio, Inc. (ANAB) came out with quarterly earnings of $0.11 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.52 per share a year ago.
Zacks Investment Research • Nov 13, 2026

Anaptys Announces Participation in Upcoming Investor Conferences
SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:
GlobeNewsWire • Nov 10, 2026

Riverwater Micro Opportunities Strategy Q3 2026 Portfolio Activity
We initiated a position in 908 Devices, a maker of portable chemical detection instruments used by hazmat teams, law enforcement, firefighters, and the military. We initiated a position in Bowhead Specialty Holdings, a specialty insurer founded in 2020 by industry veteran Stephen Sills. We exited Coastal Financial in July. Our thesis rested on its role as a banking partner to fintech companies and the operating leverage those partnerships were expected to deliver this year.
Seeking Alpha • Oct 30, 2026

Diamond Hill Small-Mid Cap Fund Q3 2026 Contributors And Detractors
The Fund declined 4.75% while the Russell 2500 Index declined 6.37%. Key contributors include Illumina, Revvity and Waystar. Key detractors include Regal Rexnord, Knife River and Red Rock Resorts.
Seeking Alpha • Oct 29, 2026

AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?
AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 27, 2026

Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today announced that GSK has received U.S. Food and Drug Administration (FDA) approval for Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/ mismatch repair deficient (dMMR) locally advanced rectal cancer.
GlobeNewsWire • Oct 19, 2026

Why This IPO Stock, An AnaptysBio Spinoff, Just Skyrocketed
First Tracks Biotherapeutics posted "impressive" results for its celiac disease treatment Monday, and the IPO stock surged by double digits.
Investors Business Daily • Oct 12, 2026

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update.
GlobeNewsWire • Sep 21, 2026

¹ Disclosures

Open an M1 investment account to buy and sell AnaptysBio Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.